Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dopamine - BrePco Biopharma

Next Previous
Drug Profile

Dopamine - BrePco Biopharma

Alternative Names: BCO-001; Neoatricon

Latest Information Update: 28 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BrePco Biopharma
  • Developer Aspire Health Science; BrePco Biopharma
  • Class Antihypotensives; Behavioural disorder therapies; Cardiotonics; Catecholamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypotension
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypotension

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for preclinical development in Hypotension(In neonates) in United Kingdom (IV, Infusion)
  • 04 Jan 2023 BrePco Biopharma expects approval from European Medicines Agency for Hypotension in mid-to late-2023 (BrePco Biopharma website; January 2023)
  • 01 Oct 2019 BrePco Biopharma terminates the phase III HIP trial in Hypotension (In Neonates) in Belgium, Canada, Czech Republic, Ireland and United Kingdom due to poor recruitment (NCT01482559)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top